IMG 9505

Campaign for Trikafta



Trikafta is a paradigm-shifting, breakthrough treatment widely heralded as having the potential to turn cystic fibrosis from a life-threatening condition, to a manageable condition. It's currently not funded in New Zealand. Help us campaign for this treatment - Kiwis with CF simply can't wait any longer. 

CFNZ Key Messages

CFNZ welcomes Pharmac’s announcement that it wants to fund Trikafta. We appreciate how quickly Pharmac has progressed Vertex’s application for Trikafta. CFNZ acknowledges the difficult decisions Pharmac has to make when deciding which medicines to fund from its limited budget, and we share Pharmac’s view that Trikafta is a paradigm-shifting treatment for cystic fibrosis (CF).

Investing in Trikafta would bring life-changing benefits to nearly 400 Kiwis with CF, their families and whānau by substantially improving their quality of life and life expectancy, and letting them live an almost normal life. Investing in Trikafta would also deliver substantial benefits to the NZ health system, through significant reductions in medical treatment, hospitalisations, and lung transplants.

CFNZ encourages Pharmac to fully recognise the life-long burden faced by Kiwis with CF, and how Trikafta would lift that burden, by ranking Trikafta very highly on its Options for Investment list.

CFNZ also urges Pharmac and Vertex to progress their commercial negotiations as quickly as possible to agree a fair and reasonable price for Trikafta – and make sure that Kiwis with CF have a future to look forward to.

Download a PDF of the Key Messages

Benefits of Trikafta for people with CF

  • Trikafta provides significant, immediate, and enduring improvements for those with CF by increasing lung function and weight gain, reducing the burden of treatment, improving quality of life, and increasing life expectancy.
  • Pharmac’s respiratory experts concluded that Trikafta is a paradigm-shifting treatment for CF and that it:
    • Provides patients with substantial improvements in quality of life and an expectation of substantial prolongation of life
    • Could allow patients with CF to live a nearly normal life.
  • The experts also concluded that Trikafta could provide substantial and meaningful improvements in quality of life and symptom burden for both those with progressed disease and younger patients who have not yet developed significant organ damage or lung impairment.
  • A number of New Zealanders have been able to access Trikafta by self-funding or through Vertex’s Managed Access Programme. As a result, they have experienced life-changing improvements in their health, well-being and ability to fully participate in life.
IMG 9458

Ashley's Trikafta Story

Meet Ashley

“Seven weeks ago, my life was pretty different. My lungs were only functioning at 22%, I was on oxygen 24/7, and I couldn’t walk to the letterbox. I could barely keep enough weight on to be considered for transplant.”

“Then I got a phone call from my CF nurse. She told me I had been approved for the Managed Access Programme for Trikafta. Two days later I took my first dose. By day three I no longer required oxygen and my appetite was coming back. After two weeks, I had the energy to enjoy life again. And that’s just the start.”

Read Ashley's full story here >

ashley module v2
IMG 9538

Benefits to the NZ Health System

Pharmac’s respiratory experts concluded that Trikafta could:

  • Reduce lung transplants for CF by 80% over time
  • Reduce hospitalisations for pulmonary infections
  • Reduce current treatments by 80% over time
  • Substantially reduce antibiotic use, particularly for intravenous and nebulised antibiotics
  • Reduce the need for dornase alfa, hypertonic saline and chest physiotherapy.

A Trikafta Success Story

Last week we (virtually) sat down with a young adult with CF and his Mum, to chat about his experience on Trikafta. As you'll read, this story is a little different from those we've shared in the last year. While he maintains a good lung function, Trikafta is treating his severe pancreatitis. And the impact it has had is life changing.

Read his story here >


Pharmac and Trikafta

  • Pharmac’s respiratory experts have reviewed the evidence for Trikafta and have recommended that it have a high priority for funding. The recommendation is for those people with CF who are 6 years or older and who have a CF mutation responsive to Trikafta.
  • Pharmac has carried out an economic assessment of Trikafta and decided to add it to the list of medicines it would like to fund – its Options for Investment list.
  • Pharmac has described Trikafta as a “paradigm-shifting” treatment for CF as it treats the cause of CF rather than the symptoms.
  • Pharmac’s Pharmaceutical and Therapeutics Advisory Committee (PTAC) will consider Trikafta at its meeting on 18/19 November 2021 and provide advice to help determine how Trikafta ranks against the other medicines Pharmac wants to fund.
  • Before it can be funded, Pharmac needs to negotiate an agreement with Vertex, consult on its proposal to fund, and ensure it has sufficient budget.

Trikafta Application Process - Pharmac

pharmac video

Trikafta petition

Trikafta for Kiwis has a petition to the Health Select Committee seeking public funding for Trikafta.  More than 37,000 people have already signed the petition, but we need as many signatures as possible before the petition closes on 28 February 2022.

You can help by sending the link to the petition to everyone you know and asking them to sign – family, friends, iwi, work colleagues, teams, clubs and anyone else you can think of.


Sign the petition for Trikafta

Going to your local media

Try to get your personal story in the local media.  Coverage in local media can help to raise awareness that CF is something that can happen to anyone. 

To help with information and background on CF and Trikafta for local media, you can use the key messages.  Make clear that Kiwis with CF can’t wait any longer for Trikafta.

Post your story

Many people have already posted their stories on social media and we thank them for doing so.  Now we need as many people as possible to share their stories – and make clear that Kiwis with CF can’t wait any longer for Trikafta.

What about Orkambi and Symdeko?

While the primary focus of this campaign is to get Trikafta funded, CFNZ’s goal is to ensure that everyone with CF who would benefit has access to a CF modulator therapy.  This includes seeking to widen the existing criteria for access to Kalydeco, and securing access to Orkambi or Symdeko for those who would not benefit or could not access Trikafta.

Campaign tracker


Keep an eye on our advocacy timeline to track how this campaign is progressing.

We'd love to know just how many emails or letters are being sent to MPs - please let us know by emailing or by copying us into the email. If you get a photo with your MP, please send this too!